Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DVA OTCMKTS:HEMA NASDAQ:OTRK NASDAQ:PGNY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDVADaVita$198.39+1.1%$153.03$101.00▼$199.27$12.74B0.841.02 million shs1.13 million shsHEMAHemaCare$25.31+0.6%$25.31$8.62▼$26.23$346.52M1.4739,950 shs5,400 shsOTRKOntrak$0.02-24.9%$0.03$0.05▼$1.78$93K1.972.80 million shs12,218 shsPGNYProgyny$23.72+23.8%$17.87$16.10▼$28.75$1.86B0.911.53 million shs4.39 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDVADaVita+1.80%+26.52%+30.95%+39.21%+36.17%HEMAHemaCare0.00%0.00%0.00%0.00%0.00%OTRKOntrak0.00%0.00%0.00%0.00%-98.56%PGNYProgyny+2.46%+3.12%+11.66%-12.71%-18.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDVADaVita$198.39+1.1%$153.03$101.00▼$199.27$12.74B0.841.02 million shs1.13 million shsHEMAHemaCare$25.31+0.6%$25.31$8.62▼$26.23$346.52M1.4739,950 shs5,400 shsOTRKOntrak$0.02-24.9%$0.03$0.05▼$1.78$93K1.972.80 million shs12,218 shsPGNYProgyny$23.72+23.8%$17.87$16.10▼$28.75$1.86B0.911.53 million shs4.39 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDVADaVita+1.80%+26.52%+30.95%+39.21%+36.17%HEMAHemaCare0.00%0.00%0.00%0.00%0.00%OTRKOntrak0.00%0.00%0.00%0.00%-98.56%PGNYProgyny+2.46%+3.12%+11.66%-12.71%-18.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDVADaVita 2.13Hold$187.83-5.23% DownsideHEMAHemaCare 0.00N/AN/AN/AOTRKOntrak 3.00Buy$3.0013,536.36% UpsidePGNYProgyny 2.69Moderate Buy$27.9118.77% UpsideCurrent Analyst Ratings BreakdownLatest DVA, PGNY, OTRK, and HEMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026DVADaVita Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$158.00 ➝ $205.005/7/2026DVADaVita BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$158.00 ➝ $194.005/7/2026DVADaVita UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$190.00 ➝ $235.005/6/2026DVADaVita Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$126.00 ➝ $220.004/6/2026DVADaVita Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/27/2026PGNYProgyny Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)3/20/2026PGNYProgyny BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$29.00 ➝ $23.003/11/2026PGNYProgyny Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$26.00 ➝ $19.003/6/2026PGNYProgyny Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.003/5/2026PGNYProgyny BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$35.00 ➝ $30.003/2/2026PGNYProgyny Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$34.00 ➝ $28.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDVADaVita$13.64B0.93$22.19 per share8.93($7.42) per share-26.71HEMAHemaCareN/AN/AN/AN/AN/AN/AOTRKOntrak$10.18M0.01N/AN/A$2.34 per share0.01PGNYProgyny$1.29B1.43$0.93 per share25.40$5.99 per share3.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDVADaVita$746.80M$9.9118.3911.690.665.65%-270.37%4.87%N/AHEMAHemaCareN/AN/AN/AN/AN/AN/AN/AN/AN/AOTRKOntrak-$25.49M-$15.81N/AN/AN/A-274.20%-269.88%-128.35%N/APGNYProgyny$58.52M$0.6535.9617.801.084.54%11.37%7.73%N/ALatest DVA, PGNY, OTRK, and HEMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026PGNYProgyny$0.44$0.50+$0.06$0.29$326.47 million$328.50 million5/5/2026Q1 2026DVADaVita$2.33$2.87+$0.54$2.87$3.36 billion$3.42 billion2/26/2026Q4 2025PGNYProgyny$0.38$0.48+$0.10$0.14$314.26 million$318.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDVADaVitaN/AN/AN/AN/AN/AHEMAHemaCareN/AN/AN/AN/AN/AOTRKOntrakN/AN/AN/AN/AN/APGNYProgynyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDVADaVitaN/A1.421.24HEMAHemaCareN/AN/AN/AOTRKOntrak0.540.720.72PGNYProgynyN/A2.732.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDVADaVita90.12%HEMAHemaCareN/AOTRKOntrak12.95%PGNYProgyny94.93%Insider OwnershipCompanyInsider OwnershipDVADaVita1.50%HEMAHemaCare26.20%OTRKOntrak1.90%PGNYProgyny9.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDVADaVita78,00064.20 million65.80 millionOptionableHEMAHemaCareN/A13.69 millionN/ANot OptionableOTRKOntrak2504.22 million4.14 millionNo DataPGNYProgyny31078.33 million70.57 millionOptionableDVA, PGNY, OTRK, and HEMA HeadlinesRecent News About These CompaniesProgyny Q1 Earnings Call Highlights2 hours ago | marketbeat.comProgyny (NASDAQ:PGNY) Shares Gap Up on Earnings BeatMay 8 at 10:10 AM | marketbeat.comProgyny, Inc. (PGNY) Q1 2026 Earnings Call TranscriptMay 8 at 5:01 AM | seekingalpha.comProgyny: Q1 Earnings SnapshotMay 8 at 1:26 AM | chron.comThe Bull Case For Progyny (PGNY) Could Change Following Flat Q1 2026 Revenue Guidance ConcernsMay 8 at 1:26 AM | finance.yahoo.comProgyny’s (NASDAQ:PGNY) Q1 CY2026 sales beat estimates, stock soarsMay 8 at 1:26 AM | msn.comProgyny (PGNY) Q1 Earnings and Revenues Beat EstimatesMay 7 at 8:05 PM | zacks.comProgyny (NASDAQ:PGNY) Updates Q2 2026 Earnings GuidanceMay 7 at 6:30 PM | marketbeat.comProgyny (NASDAQ:PGNY) Updates FY 2026 Earnings GuidanceMay 7 at 4:42 PM | marketbeat.comProgyny, Inc. Announces First Quarter 2026 ResultsMay 7 at 4:01 PM | globenewswire.comProgyny Inc (PGNY) Q1 2026: Everything You Need To Know Ahead Of EarningsMay 6 at 11:52 PM | finance.yahoo.comProgyny (PGNY) Q1 earnings report preview: What to look forMay 6 at 11:52 PM | msn.comReviewing Selectis Health (OTCMKTS:GBCS) and Progyny (NASDAQ:PGNY)May 6 at 5:37 AM | americanbankingnews.comProgyny (PGNY) Expected to Announce Earnings on ThursdayApril 30, 2026 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Acquires 70,021 Shares of Progyny, Inc. $PGNYApril 30, 2026 | marketbeat.comShould Value Investors Buy Progyny (PGNY) Stock?April 29, 2026 | zacks.comProgyny (PGNY) Upgraded to Buy: Here's WhyApril 28, 2026 | zacks.comPGNY or ALHC: Which Is the Better Value Stock Right Now?April 28, 2026 | zacks.comProgyny, Inc. (NASDAQ:PGNY) Receives Consensus Rating of "Moderate Buy" from AnalystsApril 24, 2026 | marketbeat.comProgyny, Inc. to Report Q1 2026 Financial Results on May 7, 2026April 23, 2026 | quiverquant.comQProgyny, Inc. Announces Details for Its First Quarter 2026 Results ReportApril 23, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026PepsiCo Stock Reversal Points Toward New All-Time HighsBy Thomas Hughes | April 16, 2026RPM International's Blowout Quarter Sparks a 15% Rally By Thomas Hughes | April 10, 2026Space Race 2.0: AI's Trillion-Dollar Escape PlanBy Jeffrey Neal Johnson | April 11, 2026NVIDIA’s China Connection: Investor Risks With Earnings AheadBy Thomas Hughes | May 5, 2026DVA, PGNY, OTRK, and HEMA Company DescriptionsDaVita NYSE:DVA$198.39 +2.13 (+1.09%) Closing price 03:59 PM EasternExtended Trading$198.91 +0.52 (+0.26%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.HemaCare OTCMKTS:HEMA$25.31 +0.15 (+0.60%) As of 01/3/2020HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States. The company specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols and cellular therapy. It offers human blood cellular components derived from peripheral blood, bone marrow, and cord blood; and a range of consulting services in standard operating procedure development, personnel training, and quality and regulatory compliance. The company's network of FDA-registered, GMP/GTP-compliant collection centers ensures donor materials available to customers, as well as for use within its isolation laboratory. The company has strategic partnership with Charles River Laboratories International Inc. for human immune system research. HemaCare Corporation was founded in 1978 and is headquartered in Northridge, California.Ontrak NASDAQ:OTRKOntrak, Inc. operates as an artificial intelligence powered, telehealth-enabled, and virtualized healthcare company that provides in-person services to third-party payors in the United States. Its technology-enabled platform predicts people whose chronic disease will improve with behavior change, recommends effective care pathways that people are willing to follow, and engages and guides them to and through the care they need. The company's technology enabled OnTrak program provides healthcare solutions to members with behavioral conditions that cause or exacerbate chronic medical conditions, such as diabetes, hypertension, coronary artery disease, chronic obstructive pulmonary disease, and congestive heart failure. The OnTrak integrates evidence-based psychosocial and medical interventions delivered in-person or via telehealth along with care coaching and in-market community care coordinators, who address the social and environmental determinants of health. The company was formerly known as Catasys, Inc. and changed its name to Ontrak, Inc. in July 2020. Ontrak, Inc. was incorporated in 2003 and is headquartered in Miami, Florida.Progyny NASDAQ:PGNY$23.72 +4.56 (+23.80%) Closing price 04:00 PM EasternExtended Trading$23.62 -0.09 (-0.40%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
